Viking Therapeutics (VKTX) Shares Outstanding (2014 - 2026)

Viking Therapeutics has disclosed Shares Outstanding across 13 years of filings, most recently posting $115.9 million for Q1 2026.

• Shares Outstanding for Q1 2026 came in at $115.9 million, up 3.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $115.9 million (up 3.21% YoY), and the FY2025 annual result was $114.8 million, up 2.89% from the prior year.
• Shares Outstanding came in at $115.9 million for Q1 2026 at Viking Therapeutics, up from $114.8 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $115.9 million in Q1 2026 to a low of $76.7 million in Q2 2022.
• The 5-year median for Shares Outstanding is $110.2 million (2024), against an average of $100.0 million.
• Across the five-year window, Shares Outstanding slipped 1.98% in 2022 and soared 38.97% in 2024, its largest moves.
• Viking Therapeutics' Shares Outstanding stood at $78.3 million in 2022, then increased by 27.93% to $100.1 million in 2023, then grew by 11.45% to $111.6 million in 2024, then rose by 2.89% to $114.8 million in 2025, then grew by 0.96% to $115.9 million in 2026.
• The last three Shares Outstanding figures came in at $115.9 million (Q1 2026), $114.8 million (Q4 2025), and $112.4 million (Q3 2025), per Business Quant data.